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The adoptive transfer of redirected T cells that are engi-
neered by gene transfer to express receptors that target
tumor-associated molecules and signal T cell effector func-
tions is emerging as an effective modality for cancer therapy,
and holds promise for treating a broad range of malignancies,
including those commonly managed with autologous or
allogeneic hematopoietic stem cell transplantation (HSCT). In
this review, we focus on current issues for engineering T cells
with chimeric antigen receptors (CARs) that are speciﬁc for
molecules on hematologic malignancies, and discuss the
prospects and challenges for using such Tcells either alone or
as an adjunct to HSCT to reduce the unacceptably high rates
of relapse associated with this procedure [1].CHIMERIC ANTIGEN RECEPTORS: TARGET MOLECULES
AND RECEPTOR DESIGN
Genetic modiﬁcation of T cells to confer tumor speciﬁcity
surmounts many of the technical difﬁculties associated with
isolating and expanding rare tumor-reactive T cells from
patients, and can circumvent mechanisms that interferewith
the antitumor activity of endogenous T cells by providing
control over the speciﬁcity, avidity, function, and cellular
composition of the antitumor immune response. A notable
advance in the ﬁeld of T cell engineering was the develop-
ment of chimeric antigen receptors that link recognition
domains of antibodies to molecules involved in signaling
T cell effector function [2]. CARs typically consist of a single-
chain variable fragment (scFV) derived from the VH and VL
sequences of a monoclonal antibody speciﬁc for a tumor cell
surface molecule, fused to sequences that encode a trans-
membrane domain, the CD3z signaling domain, and one or
more costimulatory signaling modules, such as CD28, 4-1BB,
OX40, or CD27 (Figure 1) [3,4]. Costimulation also can be
provided in trans by encoding separately a ligand for a cos-
timulatory receptor in the vector [5].
Although an scFV is the most common tumor recognition
domain for CARs, other molecules, such as cytokines or
peptides, that bind to tumor cells have been incorporated as
tumor-targeting domains in the CAR design [6]. CARs have
been developed that encode scFvs speciﬁc for molecules
expressed on several malignancies routinely treated with
HSCT. These include the CD19, CD20, and ROR1 molecules
expressed on B cell lymphomas and leukemias; CD33
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One potential problemwith the current targets is they do
not completely distinguish normal frommalignant cells, and
on-target toxicity to normal cells expressing the molecule is
an expected complication of therapy. This may be tolerated
temporarily for lineage-restricted molecules, such as CD19
and CD20, that are also expressed on normal mature B cells
and where i.v. immunoglobulin can be used to replace deﬁ-
cient antibody function. Nonetheless, on-target toxicity to
normal tissues remains an issue for which novel strategies to
mitigate toxicity, such as regulation of CARexpression or Tcell
survival, are needed. Exome sequencing, analysis of gene
expression proﬁles, and elucidation of glycosylation of cell
surfacemolecules on tumors versus normal cellsmay identify
novel surface molecules or isoforms that can be selectively
targeted on the malignancy without harming normal cells.
Unlike conventional T cell receptors, CARS are not MHC-
restricted, and have the advantage that a single construct
can be used to treat all patients expressing the target mole-
cule. However, CARs are synthetic, and much remains to be
understood concerning how to optimally design the receptor
construct to ensure that T cells respond appropriately in vivo
to tumor cells. The earliest CARs, termed “ﬁrst generation,”
linked the scFV to the CD3z chain and did not incorporate
costimulation into the signaling module [13]. These CARs
entered clinical trials, but signiﬁcant antitumor activity was
not observed [14,15]. The lack of in vivo activity was attrib-
uted to absent costimulation in the CAR, although it must be
acknowledged that methods for activating T cells, intro-
ducing the receptor constructs, and expanding cells for
therapy have improved markedly since that time.
Recent studies have used efﬁcient retroviral or lentiviral
transduction to introduce CARs that contain one (second-
generation) or two (third-generation) costimulatory
domains into T cells and used culture methods that rapidly
expand T cells for adoptive transfer [16]. T cells that express
second- and third-generation CARs or provide trans cos-
timulation have been shown to have more potent antitumor
activity in vitro and in animal models [4,13,17]. It must be
conceded that the optimal design for clinical applications
remains uncertain and may differ depending on the target
molecule and malignancy being treated. These issues may
eventually be resolved by clinical trials that compare distinct
constructs for both efﬁcacy and toxicity.
Other aspects of CAR design besides costimulation may
need to be considered, including the density of target
molecules on tumor cells required for effective T cell
signaling, these molecules’ proximity and accessibility on the
tumor cell membrane, and the afﬁnity of the scFv. In chronicTransplantation.
Figure 1. Basic elements of chimeric antigen receptor design.
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surface CD19 molecules is several fold greater than that of
ROR1 molecules, and how CAR occupancy might inﬂuence
T cell signaling has not yet been studied in detail. The afﬁnity
of the scFv and steric constraints imposed by the location of
the target epitopemay require alterations in the extracellular
spacer length to promote synapse formation between
effector T cells and tumor cells [18]. Structural modeling of
CARs interacting with their target molecules and measure-
ment of on and off rates of the CAR and tumor cell ligandmay
provide further insight into the optimal design of speciﬁc
CARs for individual targets.
CLINICAL APPLICATIONS OF CAR-MODIFIED T CELLS
CAR-engineered T cells have been tested for antitumor
activity in pilot clinical trials inwhich autologous T cells have
been removed from the patient, modiﬁed to express a CAR,
and reinfused into the patient after expansion in vitro.
Results of several trials of CARs speciﬁc for CD19, CD20, GD2,
and other targets have been reported [19-24]. Very prom-
ising results have been obtained targeting the B cell lineage-
restricted CD19 molecule expressed on B cell leukemias and
lymphomas with CD19-speciﬁc CAR T cells [19-22,25]. Kalos
et al. [19] reported durable remissions in patients with B cell
CLL after the infusion of autologous T cells transduced to
express a CD19-speciﬁc CAR containing a 4-1BB cos-
timulatory domain. In these studies, low-dose T cell infusion
led to in vivo expansion and persistence of CAR T cells,
subsequent tumor lysis, and a sustained deﬁciency of normal
CD19þ B cells. Signiﬁcant antitumor activity, depletion of
normal B cells, and side effects related to tumor lysis and
cytokine release also have been reported in patients with CLL
and lymphoma by groups at the National Institutes of Health,
Memorial Sloan Kettering Cancer Center, and Baylor College
of Medicine in trials in which autologous T cells were
modiﬁed to express CD19 CARs containing a CD28 cos-
timulatory domain [20,22,26]. The ﬁnding that durable
responses can be achieved in patients with advanced B cell
malignancies illustrates the potency of CAR T cells, and
suggests that future work to deﬁne optimal CD19 CAR
constructs and to integrate T cell therapy earlier after diag-
nosis or after autologous HSCT, in which marked tumor
cytoreduction can be achieved by intensive conditioning,
may improve outcome and reduce the toxicity resulting from
CAR-mediated tumor lysis.
The success of targeting CD19 on tumor cells predictably
leads to the elimination of normal mature and immature
B cells that also express CD19. Moreover, because CD19 is
expressed when hematopoietic stem cells commit to the
B cell lineage, no new B cells would be expected to emerge as
long as the transferred T cells survive, express the CAR, and
remain functional. Strategies to regulate survival of CART cells or turn off CAR expression are being developed, as
discussed below, and could allow the regeneration of normal
B cells from hematopoietic progenitors. CD20 and ROR1 are
alternative targets on B cell malignancies; however, CD20 is
also expressed on normal B cells and would be expected to
result in B cell depletion. ROR1, which is uniformly expressed
on CLL, mantle cell lymphoma, and a subset of acute
lymphoblastic leukemia, is not expressed onmature B cells in
the periphery and could spare this compartment [8]. ROR1 is
expressed transiently on early B cell precursors in the bone
marrow and on some normal tissues; thus, toxicity remains
a concern with targeting ROR1. Animal studies exploring the
safety of ROR1 as a target for CAR therapy are in progress.
CAR-modiﬁed T cells also may have applications in solid
tumors, including those in children that can be managed
with high-dose therapy and autologous HSCT. Candidate
surface molecules on solid tumors, including mesothelin,
folate receptor, L1CAM, and GD2, have been identiﬁed and
are being developed for clinical applications. Signiﬁcant
antitumor activity without toxicity has been reported in
patients with neuroblastoma treated with T cells modiﬁed
with a ﬁrst-generation GD2 CAR [27]. The persistence of the
transferred cells was relatively short in that study, however,
perhaps owing to the lack of costimulation in the CAR. GD2 is
expressed on normal peripheral nerves, and on-target
toxicity from a sustained T cell response will need to be
monitored if more potent CARs are used [24].
COMPOSITION OF CAR T CELL PRODUCTS
The initial clinical applications of CAR T cells have
primarily derived cell products for administration by
inserting the CAR gene into unselected polyclonal T cells
obtained from the patient by leukapheresis. It is now well
established that the peripheral T cell pool contains different
proportions of naïve and memory CD4þ and CD8þ cell
subsets, and that these subsets diverge in function, tran-
scriptional proﬁles, and epigenetic programming, with
potential consequences for their efﬁcacy in adoptive therapy
[28]. Direct comparisons have revealed profound differences
in the ability of T cells from different subsets to persist long
term in vivo and revert to the memory pool. For example, in
animal models, the adoptive transfer of CD8þ CD62Lþ central
memory T cells (TCM) or a rare subset of CD62Lþ memory
T cells (memory stem cells [TSCM]) with cell surface markers
shared by both naïve (TN) and TCM cells, exhibits superior
survival in vivo and/or mediate superior antitumor activity
compared with more differentiated CD62L effector memory
(TEM) cells [29-31]. CD8þ TN cells are undifferentiated and
have long telomeres and substantial proliferative capacity,
and thus might be directed by cytokines or small molecules
during in vitro expansion and transduction to have proper-
ties that confer superior antitumor activity [32]. The CD4þ
T cell compartment is also heterogeneous, with deﬁned
naïve, memory and FoxP3þ regulatory subsets [33]. CD4þ
T cells alone have been shown to exhibit antitumor activity
after adoptive transfer in animal models and humans, at least
in part by providing help for CD8þ T cells [34], and the
potential to formulate CAR-modiﬁed T cell products that
contain deﬁned proportions of CD8þ and CD4þ T cells from
distinct subsets is beginning to be explored. Because the
phenotypic distribution of T cells in the blood is inﬂuenced
by age, pathogen exposure, and previous chemotherapy, the
use of unselected populations for gene transduction results
in a lack of uniformity in the composition of T cell products
administered to individual patients, and could affect potency
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subsets for therapy is the additional cost and time associated
with deriving the cell products for therapy. Transduction of
unselected T cells should provide some proportion of T cells
with the desired traits and may be sufﬁcient for efﬁcacy in
malignancies sensitive to immunotherapy. However, differ-
ences in the composition of cell products will make it difﬁ-
cult to deﬁne doseeresponse relationships and to ensure
immediate potency against less-responsive tumors.
INCORPORATING CAR T CELLS INTO HSCT REGIMENS
The antitumor activity of autologous CD19 CAR T cells in
patients with advanced B cell malignancies illustrates the
potential to incorporate the administration of Tcellsmodiﬁed
with a CAR to reduce relapse afterautologousHSCT, and touse
donor T cells modiﬁed with a CAR to augment the graft-
versus-leukemia effect of allogeneic HSCT. The importance
of lymphodepleting chemoradiotherapy for improving the
persistence and antitumor efﬁcacy of transferred T cells has
been established in studies inmelanoma [35], suggesting that
intensive conditioning administered before autologous HSCT
could provide an ideal environment for administering CAR T
cells. Studies targeting CD19 in patients with lymphoma
undergoing autologous HSCT are in progress, and the results
will be of interest. If this approach proves effective, it could
lead to renewed efforts to use intensive conditioning and
autologous HSCT combined with T cell immunotherapy for
selected solid tumors that express unique cell surface mole-
cules for which CARs have been designed.
Leukemia relapse remains a major cause of failure after
allogeneic HSCT, and the long- sought goal of augmenting the
graft-versus-leukemia effect without aggravating GVHD
remains elusive. This potentially could be accomplished using
CAR Tcells; however, in this setting, the composition of CAR T
cell productswill be critical, toprevent infusionof alloreactive
T cells that can cause GVHD. One strategy involves selecting
donor CD8þ cytomegalovirus or Epstein-Barr virusespeciﬁc T
cells that have been administered without GVHD in previous
studies [36], andengineering these cells to express the tumor-
reactive CAR [37]. In principle, virus-speciﬁc CD4þ T cells
could be modiﬁed similarly if the presence of both subsets in
the cell product is essential for therapeutic efﬁcacy. Clinical
trials of CD19 CAR-modiﬁed T cells after allogeneic HSCT are
currently accruing patients, which should assist in deﬁning
both the potential for efﬁcacy and limitations of this approach
in patients with B cell malignancies. Ideally, CARs speciﬁc for
molecules on myeloid leukemias will soon be validated and
advance to clinical testing to provide therapeutic options for
this subset of patients.
MODIFICATIONS TO ENHANCE THE SAFETY AND
EFFICACY OF CAR T CELLS
Because most of the current CARs do not completely
differentiate normal and malignant cells, strategies to
improve safety are a signiﬁcant area of research. A condi-
tional suicide gene that encodes human caspase 9 fused to
a modiﬁed human FK-binding protein confers sensitivity to
a synthetic small molecule that induces apoptosis through
activation of caspase 9. This approach effectively ablated
alloreactive T cells in a clinical trial after human HSCT, and
may prove useful in abrogating on-target or off-target
toxicities of CAR-engineered T cells [38]. Expression of
CARs through RNA transfection of T cells ensures a gradual
loss of surface CAR expression as T cells divide and may be
a useful strategy for deﬁning the potential toxicity of novelconstructs [39]. Another approach is to regulate expression
of the tumor-targeting CAR by placing it under the control of
regulatory elements that can be turned on (or off) by deliv-
ering a small molecule [40].
Strategies to improve efﬁcacy also will likely be necessary
as clinical trials are extended to more aggressive tumors.
Genetic strategies to overcome local tumor immunosup-
pression mediated by stromal cells, cytokines, and negative
signaling pathways in T cells have been devised. One
approach expresses a single-chain IL-12 molecule in tumor-
speciﬁc T cells to reprogram tumor-associated myeloid cells
and eliminate the need for lymphodepleting chemotherapy
before CAR T cell therapy [41]. Gene editing technology could
allow permanent disruption of negative signaling pathways
such as PD-1, although combinatorial approaches using
blocking antibodies that themselves have some efﬁcacy may
be a more convenient approach [42]. The development of
strategies to enhance efﬁcacy will be best accomplished by
careful analysis of treated patients to deﬁne the basis for
success and failure.CONCLUSION
Immunotherapy for cancer has undergone a renaissance
in recent years, based both on technological developments,
such as the ease of introducing genes into T cells, and on an
improved understanding of the obstacles to eradicating
cancer through immune mechanisms. Although much
remains to be discovered, there is considerable optimism
that this modality can have a meaningful impact for patients,
both alone and as an adjunct to HSCT.ACKNOWLEDGMENTS
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